Severe COVID-19 pneumonia

[키워드] 1:1 48 hour Admission allergic reaction anticipated application AST/ALT Bacterial infection Bacterial infections blinded block Breast feeding clinical clinical trial Combination concealed conducted Contraception Control COVID-19 COVID-19 patient criteria defined dependent on Desirable diagnostic Diaphragm dissemination dose double blind ECMO Efficacy Efficacy and safety element Endpoint evaluate extracorporeal membrane oxygenation failure female Germany Hospital stay Hydroxychloroquine IL-6-Rezeptor blockade Immunosuppression immunosuppressive therapy IMV independent Inflammation ingredient Injury Inpatient intensive care units interfere Invasive mechanical ventilation investigator investigators less life lung failure mechanical ventilation methotrexate NaCl NIV non-invasive ventilation number objective outcome parallel group parameters participant Participation Pathogenesis Patient patients PCT performed placebo-controlled trial Pneumonia polymerase chain positive Prednisolone produced progression proof protocol Pulmonary function pulmonary inflammation Quality of life randomisation randomised randomised controlled trial recruited reduce Registered respiratory Safe Sample size SARS-CoV-2 SARS-CoV2 SARS-CoV2 infection SAS severe COVID-19 Severe COVID-19 pneumonia Simultaneous single dose status stratified Study protocol sulfasalazine System the patient therapy Tocilizumab Treatment Trial trials Tuberculosis ULN unit Ventilation ventilator ventilator free day ventilator free days VFD Viral hepatitis website
[DOI] 10.1186/s13063-020-04447-3 PMC 바로가기 [Article Type] Letter